Psoriasis: Targets and Therapy

Código QR

Psoriasis: Targets and Therapy

Guardado en:

Detalles Bibliográficos
Formato:	journal
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	skin diseases psoriasis psoriatic arthritis Dermatology RL1-803
Acceso en línea:	https://doaj.org/toc/2230-326X
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The metabolomics of psoriatic disease
por: Yan D, et al.
Publicado: (2017)

Association of HLA Alleles and HLA Haplotypes with Psoriasis, Psoriatic Arthritis and Disease Severity in a Miscegenated Population
por: Cassia FF, et al.
Publicado: (2021)

A Successful Treatment of Ostraceous Psoriasis Associated with Psoriatic Arthritis in Children: A Case Report
por: Rowawi R, et al.
Publicado: (2020)

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
por: Chiricozzi A, et al.
Publicado: (2019)

The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy
por: van Muijen ME, et al.
Publicado: (2020)

Local effects of adipose tissue in psoriasis and psoriatic arthritis
por: Kruglikov IL, et al.
Publicado: (2017)

Impact of Etanercept on Vitamin D Status and Vitamin D-binding Protein in Bio-naïve Patients with Psoriasis
por: Maria Siekkeri Vandikas, et al.
Publicado: (2021)

Psoriasis to Psoriatic Arthritis: The Application of Proteomics Technologies
por: Fei Qi, et al.
Publicado: (2021)

Genetic markers for psoriatic arthritis in patients with psoriasis. Part I: non-HLA genes
por: Alexey A. Kubanov, et al.
Publicado: (2021)

Frequency of Health Care Resource Utilization and Direct Medical Costs Associated with Psoriatic Arthritis in a Rheumatic Care Center in Colombia
por: Santos-Moreno P, et al.
Publicado: (2021)

The role of endothelial damage and dyslipidemia in the development of cardiovascular pathology in psoriatic arthritis
por: Zarema R. Khismatullina, et al.
Publicado: (2021)

Pustular psoriasis: pathophysiology and current treatment perspectives
por: Benjegerdes KE, et al.
Publicado: (2016)

Dermoscopic hemorrhagic dots: an early predictor of response of psoriasis to biologic agents
por: Aimilios Lallas, et al.
Publicado: (2016)

Updates on the Treatment of Erythrodermic Psoriasis
por: Lo Y, et al.
Publicado: (2021)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
por: Ly K, et al.
Publicado: (2019)

Quality of life in patients with psoriatic arthritis
por: Kseniya Mikhailovna Koreshkova, et al.
Publicado: (2021)

Psoriasis and alcohol
por: Svanström C, et al.
Publicado: (2019)

Psoriasis in children
por: Pinson R, et al.
Publicado: (2016)

Current knowledge on psoriasis and autoimmune diseases
por: Ayala-Fontánez N, et al.
Publicado: (2016)

Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
por: Annunziata Dattola, et al.
Publicado: (2021)

Psoriasis and uveitis: links and risks
por: Fotiadou C, et al.
Publicado: (2019)

IMMUNE PATHOGENESIS OF PSORIASIS AND PSORIATIC ARTHRITIS
por: S. V. Smirnova, et al.
Publicado: (2014)

Tacrolimus for the management of psoriasis: clinical utility and place in therapy
por: Malecic N, et al.
Publicado: (2016)

Clinical evidence of therapy for genital psoriasis by biologic agents
por: Evgeny V. Sokolovskiy, et al.
Publicado: (2021)

Management of scalp psoriasis: current perspectives
por: Blakely K, et al.
Publicado: (2016)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado Á, et al.
Publicado: (2018)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton P, et al.
Publicado: (2021)

The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice
por: Georgios Kokolakis, et al.
Publicado: (2021)

GENETIC FACTORS IN IMMUNOPATHOGENESIS OF PSORIASIS AND PSORIATIC ARTHRITIS
por: M. V. Smolnikova, et al.
Publicado: (2014)

Psoriasis and Cardiometabolic Diseases: The Impact of Inflammation on Vascular Health
por: Teklu M, et al.
Publicado: (2021)

Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic
por: Haulrig MB, et al.
Publicado: (2021)

Perspective trends of topical therapy of patients with psoriasis
por: Alexander S. Zhukov, et al.
Publicado: (2021)

Serum TSLP is a potential biomarker of psoriasis vulgaris activity
por: El-Ghareeb MI, et al.
Publicado: (2019)

Assessment and monitoring of biologic drug adverse events in patients with psoriasis
por: Hanley T, et al.
Publicado: (2016)

Diagnosis and screening of patients with generalized pustular psoriasis
por: Ly K, et al.
Publicado: (2019)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: Riccardo G. Borroni, et al.
Publicado: (2021)

An Atypical Case of Pustular Psoriasis Presenting With Severe Subungual Abscesses Involving All Fingers
por: A. Tulin Mansur
Publicado: (2019)

Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy
por: Flatz L, et al.
Publicado: (2013)

Single-center, noninterventional clinical trial to assess the safety, efficacy, and tolerability of a dimeticone-based medical device in facilitating the removal of scales after topical application in patients with psoriasis corporis or psoriasis capitis
por: Hengge UR, et al.
Publicado: (2017)

Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry
por: Gudbjornsson B, et al.
Publicado: (2018)